8-K: Travere Therapeutics Reports Strong Fourth Quarter and Full Year 2024 Financial Results, FILSPARI Sales Outperform

Travere Therapeutics announces positive Q4 and full-year 2024 financial results, driven by strong FILSPARI sales and provides updates on its clinical programs.

Summary

• Travere Therapeutics reported its fourth quarter and full year 2024 financial results on February 20, 2025.
• Net product sales for Q4 2024 were $73.5 million, compared to $39.9 million for the same period in 2023.
• Full year 2024 net product sales reached $226.7 million, up from $127.5 million in 2023, driven by FILSPARI sales.
• FILSPARI net product sales were $49.6 million in Q4 2024 and $132.2 million for the full year 2024.
• The company had $370.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, including $134.7 million from a common stock offering in November 2024.
• Travere plans to submit a supplemental New Drug Application (sNDA) for FILSPARI in FSGS around the end of Q1 2025.
• They anticipate restarting enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026.
• The FDA assigned a PDUFA target action date of August 28, 2025, to the company's sNDA requesting modification of liver monitoring for FILSPARI in IgAN.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, progress in clinical development, and positive management commentary. The company's focus on rare diseases and its lead product, FILSPARI, contribute to a favorable sentiment.

Positives

• FILSPARI's commercial launch is exceeding expectations.
• The FDA granted full approval to FILSPARI for IgAN.
• The company is progressing with its sNDA submission for FILSPARI in FSGS.
• Travere has a strong cash position of $370.7 million.
• FILSPARI is recommended as a foundational kidney-targeted therapy in draft KDIGO guidelines.
• CSL Vifor has launched FILSPARI for the treatment of IgAN in Germany, Austria and Switzerland.

Negatives

• Research and development expenses remain high, although they decreased from $245.0 million in 2023 to $217.5 million in 2024.
• The company reported a net loss of $321.5 million for the full year 2024.
• The company is dependent on the FDA accepting the sNDA for filing, granting priority review of the sNDA or granting approval of FILSPARI for FSGS.

Risks

• The FDA may not approve FILSPARI for FSGS.
• Clinical trials may face delays or fail.
• The company faces competition from other therapies.
• Manufacturing scale-up for pegtibatinase presents challenges.
• The company's dependence on contractors for clinical drug supply and commercial manufacturing.
• Global and macroeconomic conditions, including health epidemics and pandemics, could disrupt clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

Travere Therapeutics is focused on the continued commercial launch of FILSPARI, the sNDA submission for FILSPARI in FSGS, and restarting enrollment in the Phase 3 HARMONY Study for pegtibatinase. They anticipate potential milestone payments from partners and further data presentations to support FILSPARI's use.

Management Comments

• Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, stated that 2024 was a remarkable year for the company and the patients they serve.
• He highlighted the strong commercial launch of FILSPARI and its potential as a foundational therapy for IgAN.
• He noted the company's commitment to reaching more patients at risk of IgAN progression.

Industry Context

Travere's focus on rare kidney diseases positions it within a niche market with significant unmet needs. The full approval of FILSPARI for IgAN and the potential approval for FSGS could establish it as a leader in this space. Competition exists from companies developing alternative therapies for these conditions, but Travere's progress and partnerships provide a competitive advantage.

Comparison to Industry Standards

• FILSPARI's performance can be compared to other drugs targeting rare kidney diseases, such as Calliditas Therapeutics' Tarpeyo (budesonide) for IgAN.
• Tarpeyo achieved peak sales of approximately $90 million in 2023, suggesting that FILSPARI's $132.2 million in sales for 2024 indicates a strong market uptake.
• Travere's R&D spending is in line with other biopharmaceutical companies focused on rare diseases, such as Horizon Therapeutics and Alexion Pharmaceuticals, which invest heavily in clinical development.
• The company's cash position is adequate to support its ongoing clinical programs and commercial activities, comparable to other companies of similar size and stage.

Stakeholder Impact

• Shareholders: Positive financial results and clinical progress are likely to be viewed favorably.
• Patients: Potential approval of FILSPARI for FSGS would provide a new treatment option for a rare kidney disorder.
• Employees: Continued growth and success of the company could lead to job security and opportunities.
• Partners: Collaboration with CSL Vifor and Renalys Pharma benefits all parties involved.

Next Steps

• Submission of an sNDA for FILSPARI in FSGS around the end of Q1 2025.
• Potential FDA approval of FILSPARI for FSGS.
• Restarting enrollment in the Phase 3 HARMONY Study for pegtibatinase in 2026.
• Conversion of the conditional marketing authorization (CMA) for FILSPARI for the treatment of IgAN in Europe to full approval.
• Presentation of additional data from ongoing clinical studies to further support FILSPARI as foundational therapy in treating patients with IgAN.
• Final publication of the updated Kidney Disease Improving Global Outcomes (KDIGO) clinical guidelines for IgAN.
• Expansion of the ongoing SPARTAN Study to include post-kidney transplant patients with recurring IgAN and plans to initiate a new open label study of FILSPARI in post kidney-transplant patients with recurrent IgAN or FSGS.
• Topline results from Renalys Pharma's registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the second half of 2025.

Key Dates